IMCR
Immunocore Holdings PLC - ADR

499
Loading...
Loading...
News
all
press releases
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi
Iovance shares plunge after Q2 miss and voluntary withdrawal of Amtagvi's EU filing, despite strong U.S. sales growth for the therapy.
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y
NKTR's second-quarter top and bottom lines beat estimates. Studies on the lead candidate, rezpeg, are progressing well.
Zacks·1mo ago
News Placeholder
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.
Zacks·1mo ago
News Placeholder
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues
Puma Biotechnology tops second-quarter earnings and revenue estimates as rising Nerlynx sales drive growth.
Zacks·1mo ago
News Placeholder
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
Mirum surges after second-quarter earnings and revenues top estimates, driven by Livmarli growth and a raised 2025 outlook.
Zacks·1mo ago
News Placeholder
Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates
VTRS beats on Q2 estimates with strength in branded drugs and growth in Greater China, lifting shares.
Zacks·1mo ago
News Placeholder
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX beats Q2 earnings and revenue estimates as Firdapse and Agamree drive strong top-line growth.
Zacks·1mo ago
News Placeholder
Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
Zacks·1mo ago
News Placeholder
Compared to Estimates, Immunocore (IMCR) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Immunocore (IMCR) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·1mo ago
News Placeholder
ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum
ADMA Biologics' Q2 earnings and revenue beat can be attributed to Asceniv growth. However, shares fall 7.4% in after-hours trading.
Zacks·1mo ago

Latest IMCR News

View

Advertisement. Remove ads.

Advertisement. Remove ads.